Why is epoprostenol not prescribed as oral tablets for thrombosis prevention?

The drug degrades extremely rapidly in the bloodstream, with a half-life of only about 2 minutes. Continuous infusion is required to maintain the effect, making oral administration impossible.

What does the term 'functional antagonist of thromboxane A2' mean?

It means that the drug stimulates its own (prostacyclin) receptors but produces physiological effects directly opposite to those of thromboxane $A_2$. Thromboxane promotes aggregation, whereas prostacyclin reduces it.

What is the main indication for prescribing prostacyclin analogs?

The primary clinical indication is the treatment of pulmonary arterial hypertension, achieved through their profound vasodilating effects.

Where is the antiplatelet effect of these drugs utilized, given their short duration of action?

Due to their short half-life, they are not widely used for outpatient antiplatelet therapy, but a potential niche is preventing platelet aggregation during extracorporeal circulation procedures.

Home › Pharmacology › Prostacyclin Receptor Agonists

Prostacyclin Receptor Agonists

Epoprostenolum

For medical students2 min readUpdated 2026-10-10

Prostacyclin receptor agonists are a class of pharmacological agents that closely mimic the effects of the natural endogenous antiplatelet agent prostacyclin. They act as potent vasodilators and inhibitors of platelet aggregation, serving as functional antagonists of thromboxane $A_2$.

Representative drugEpoprostenol (synthetic prostacyclin)

Duration of actionHalf-life ($t_{1/2}$) is approximately 2 minutes

Primary effectReduced platelet aggregation and marked vasodilation

Clinical applicationManagement of pulmonary hypertension

Mechanism of Action and Pharmacological Effects

Drugs in this class, with epoprostenol as the primary representative, act by directly stimulating specific prostacyclin receptors. They replicate the effects of endogenous prostacyclin, which normally functions as a natural antiplatelet agent.

A key pharmacodynamic feature of these agents is that they act as functional antagonists of thromboxane $A_2$. This means they produce effects directly opposite to those of thromboxane while binding to their own distinct receptors.

Key pharmacological effects:

Antiplatelet effect: The drugs effectively reduce the ability of platelets to aggregate, preventing them from clumping together.
Vascular effect: Marked vasodilation occurs, which naturally leads to a systemic decrease in blood pressure.

Pharmacokinetic Features

The pharmacokinetics of prostacyclin analogs are exceptionally unique, imposing strict limitations on their administration routes. The main clinical challenge lies in the extremely short half-life of the active substance in systemic circulation.

The half-life ($t_{1/2}$) of epoprostenol is only about two minutes. Upon entering the bloodstream, the drug molecule undergoes rapid degradation. Due to this swift inactivation, traditional routes of administration (such as oral intake, intramuscular injections, or sublingual use) are completely ineffective.

To maintain a therapeutic concentration and ensure a stable pharmacological effect, the drug requires continuous intravenous infusion. Only continuous infusion can compensate for the rapid breakdown of the substance in blood plasma and sustain the necessary level of vasodilation and antiplatelet activity.

Clinical Application

The specific profile of action and complex pharmacokinetics define a rather narrow niche for these medications in modern medical practice.

Treatment of pulmonary hypertension. This is the primary indication for this drug class. Therapeutic success is achieved through a pronounced vasodilatory effect, which effectively lowers pulmonary vascular resistance and pressure.
Prevention of thrombosis (limited use). Despite their potent antiplatelet potential, these drugs are not widely used as standard agents for thrombosis prevention. The major limiting factor is their extremely short duration of action. However, a potential clinical niche is the prevention of platelet aggregation during extracorporeal circulation (e.g., cardiopulmonary bypass), where continuous control over blood clotting within the circuit is required.

Mnemonic

Epoprostenol: An EPOch of PROSTate simplicity lasts only 2 minutes. For vessels to stay wide and platelets un-stuck, the IV drip must run non-stop.

Frequently asked questions

Why is epoprostenol not prescribed as oral tablets for thrombosis prevention?: The drug degrades extremely rapidly in the bloodstream, with a half-life of only about 2 minutes. Continuous infusion is required to maintain the effect, making oral administration impossible.
What does the term 'functional antagonist of thromboxane A2' mean?: It means that the drug stimulates its own (prostacyclin) receptors but produces physiological effects directly opposite to those of thromboxane $A_2$. Thromboxane promotes aggregation, whereas prostacyclin reduces it.
What is the main indication for prescribing prostacyclin analogs?: The primary clinical indication is the treatment of pulmonary arterial hypertension, achieved through their profound vasodilating effects.
Where is the antiplatelet effect of these drugs utilized, given their short duration of action?: Due to their short half-life, they are not widely used for outpatient antiplatelet therapy, but a potential niche is preventing platelet aggregation during extracorporeal circulation procedures.

Go deeper

Mechanisms of vasodilation upon prostacyclin receptor stimulation.
Interaction between prostacyclin and thromboxane $A_2$ in hemostasis.
Dosage considerations during continuous infusion of epoprostenol.
Role of the vasodilatory effect in managing pulmonary hypertension.
The challenge of platelet aggregation during extracorporeal circulation.